- Home
- RGA vs PEN Comparison
RGA vs PEN Comparison
Compare RGA & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGA | PEN |
|---|---|---|
| Founded | 1973 | 2004 |
| Country | United States | United States |
| Employees | 4300 | N/A |
| Industry | Life Insurance | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 12.5B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | RGA | PEN |
|---|---|---|
| Price | $215.79 | $316.39 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 16 |
| Target Price | $241.50 | ★ $360.14 |
| AVG Volume (30 Days) | 326.2K | ★ 365.8K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | ★ 1155.56 |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | ★ $1,403,665,000.00 |
| Revenue This Year | $11.38 | $14.34 |
| Revenue Next Year | $6.11 | $13.71 |
| P/E Ratio | ★ $12.58 | $384.80 |
| Revenue Growth | N/A | ★ 17.50 |
| 52 Week Low | $165.52 | $221.26 |
| 52 Week High | $229.21 | $362.41 |
Technical Indicators
Market Signals| Indicator | RGA | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 40.31 |
| Support Level | $203.56 | $315.03 |
| Resistance Level | $221.90 | $322.24 |
| Average True Range (ATR) | 4.61 | 2.38 |
| MACD | 0.93 | 0.11 |
| Stochastic Oscillator | 85.06 | 24.43 |
Price Performance
Historical ComparisonAbout RGA Reinsurance Group of America Incorporated
Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.